marketcap
Facebook
Twitter
Telegram
Report an ErrorGW Pharmaceuticals plc General and Administrative Expenses 2011-2025 | GWPH
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses GW Pharmaceuticals plc
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 336 M | 260 M | - | - | - | - | 11.9 M | 6.13 M | - | 1.22 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 336 M | 1.22 M | 123 M |
General and Administrative Expenses of other stocks in the Drug manufacturers industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Amryt Pharma plc
AMYT
|
92 M | $ 14.7 | - | $ 621 M |  Britain |
 |
Aerie Pharmaceuticals
AERI
|
138 M | $ 15.25 | - | $ 754 M |  USA |
 |
PetIQ
PETQ
|
196 M | $ 13.6 | 1.64 % | $ 400 M | USA |
 |
Agile Therapeutics
AGRX
|
10.5 M | $ 0.6 | 10.11 % | $ 58.2 M | USA |
 |
Teligent, Inc.
TLGT
|
23.4 M | $ 0.173 | -13.85 % | $ 16.1 M | USA |
 |
Recro Pharma
REPH
|
21 M | $ 1.4 | -4.76 % | $ 65.3 M | USA |
 |
Athenex
ATNX
|
44.9 M | $ 0.2 | -23.39 % | $ 1.76 M | USA |
 |
Ironwood Pharmaceuticals
IRWD
|
144 M | $ 1.58 | 3.95 % | $ 251 M | USA |
 |
PLx Pharma
PLXP
|
40 M | $ 0.09 | -27.8 % | $ 2.56 M | USA |
 |
Shineco, Inc.
TYHT
|
9.22 M | $ 11.09 | -3.90 % | $ 97.2 M |  China |
 |
Lannett Company
LCI
|
81 M | $ 0.66 | 1.15 % | $ 7.11 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
390 M | $ 40.0 | -0.1 % | $ 2.03 B |  Schweden |
 |
Adamas Pharmaceuticals, Inc.
ADMS
|
107 M | $ 8.22 | - | $ 376 M | USA |
 |
Organogenesis Holdings
ORGO
|
295 M | $ 4.13 | -0.24 % | $ 544 M | USA |
 |
Flexion Therapeutics, Inc.
FLXN
|
105 M | $ 9.12 | - | $ 459 M | USA |
 |
Happiness Biotech Group Limited
HAPP
|
9.13 M | $ 4.5 | 1.35 % | $ 17.8 M | China |
 |
Kindred Biosciences, Inc.
KIN
|
22 M | $ 9.25 | 0.11 % | $ 419 M | USA |
 |
Neos Therapeutics, Inc.
NEOS
|
13.2 M | $ 1.15 | -2.54 % | $ 57.2 M | USA |
 |
Endo International plc
ENDP
|
568 M | $ 0.29 | - | $ 28.9 M |  Irlanda |
 |
Tricida
TCDA
|
37.6 M | $ 0.11 | - | $ 3.25 M | USA |
 |
PPD, Inc.
PPD
|
1.01 B | $ 47.25 | 0.13 % | $ 16.6 B | USA |
 |
Bausch Health Companies
BHC
|
2.92 B | $ 6.34 | -0.78 % | $ 2.31 B |  Canada |
 |
HEXO Corp.
HEXO
|
58.2 M | $ 0.71 | 2.45 % | $ 38.1 M | - |
 |
Veru
VERU
|
31.2 M | $ 4.41 | 1.38 % | $ 595 M | USA |
 |
Neptune Wellness Solutions
NEPT
|
64.7 M | $ 0.2 | -45.3 % | $ 917 K | Canada |
 |
Taro Pharmaceutical Industries Ltd.
TARO
|
57.1 M | $ 42.97 | - | $ 1.62 B |  Israel |
 |
Viatris
VTRS
|
4.18 B | $ 9.97 | -1.68 % | $ 12.1 B | USA |
 |
Horizon Therapeutics Public Limited Company
HZNP
|
1.54 B | $ 116.3 | - | $ 26.6 B | Irlanda |
 |
FSD Pharma
HUGE
|
15.9 M | $ 5.84 | 5743.5 % | $ 69.7 M | Canada |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
13.2 M | $ 0.78 | 0.86 % | $ 117 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
14.2 M | $ 1.3 | - | $ 55.5 M | USA |
 |
Guardion Health Sciences
GHSI
|
9.58 M | $ 3.25 | -0.31 % | $ 3.64 M | USA |
 |
Alimera Sciences
ALIM
|
18.5 M | $ 5.54 | - | $ 142 M | USA |
|
Qilian International Holding Group Limited
QLI
|
3.25 M | $ 5.41 | -6.08 % | $ 184 M | China |
 |
Amneal Pharmaceuticals
AMRX
|
476 M | $ 5.91 | 2.6 % | $ 892 M | - |
 |
Avadel Pharmaceuticals plc
AVDL
|
181 M | $ 14.21 | -1.8 % | $ 1.35 B |  France |
 |
Johnson & Johnson
JNJ
|
22.9 B | $ 189.69 | 0.42 % | $ 457 B | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
11.1 M | $ 3.67 | 3.2 % | $ 51.6 M | USA |
 |
Aurora Cannabis
ACB
|
119 M | $ 6.1 | -1.13 % | $ 86.3 M | - |
 |
Eagle Pharmaceuticals
EGRX
|
107 M | $ 2.14 | -39.89 % | $ 27.7 M | USA |
 |
OrganiGram Holdings
OGI
|
12.8 M | $ 1.94 | -1.02 % | $ 402 M | Canada |
 |
Emergent BioSolutions
EBS
|
368 M | $ 9.89 | -0.3 % | $ 506 M | USA |
 |
GlaxoSmithKline plc
GSK
|
11 B | $ 43.35 | -0.34 % | $ 173 B | Britain |
 |
Radius Health
RDUS
|
131 M | $ 30.0 | - | $ 1.42 B | USA |
 |
Solid Biosciences
SLDB
|
33.3 M | $ 6.31 | 14.31 % | $ 258 M | USA |
 |
Catalent
CTLT
|
935 M | $ 63.48 | - | $ 11.5 B | USA |
 |
Pacira BioSciences
PCRX
|
294 M | $ 23.41 | -0.89 % | $ 1.08 B | USA |
 |
Biogen
BIIB
|
2.4 B | $ 150.97 | -0.81 % | $ 22 B | USA |